Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?

Autor(es)

da Silva, Lais Teodoro ^[1] ; Santillo, Bruna Tereso ^[1] ; de Almeida, Alexandre ^[1] ; da Silva Duarte, Alberto Jose ^[1] ; Oshiro, Telma Miyuki ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Invest Dermatol & Imunodeficiencias, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: FRONTIERS IN IMMUNOLOGY; v. 9, DEC 18 2018.
• Citações Web of Science: 5

Resumo

Harnessing dendritic cells (DC) to treat HIV infection is considered a key strategy to improve anti-HIV treatment and promote the discovery of functional or sterilizing cures. Although this strategy represents a promising approach, the results of currently published trials suggest that opportunities to optimize its performance still exist. In addition to the genetic and clinical characteristics of patients, the efficacy of DC-based immunotherapy depends on the quality of the vaccine product, which is composed of precursor-derived DC and an antigen for pulsing. Here, we focus on some factors that can interfere with vaccine production and should thus be considered to improve DC-based immunotherapy for HIV infection. (AU)

• Processo FAPESP: 18/12460-0 - Produção e caracterização de células dendríticas polarizantes aDC1 para protocolo clínico de imunoterapia anti-HIV
• Beneficiário: Laís Teodoro da Silva
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/25212-9 - Vacina terapêutica baseada em células dendríticas aDC1 e vírus autólogo inativado visando o controle viral de indivíduos infectados pelo HIV-1 em interrupção de terapia antirretroviral
• Beneficiário: Alberto José da Silva Duarte
• Linha de fomento: Auxílio à Pesquisa - Temático